Phyloncology, Inc.

CANCER EARLY DETECTION AND DIAGNOSIS

Diagnosing Cancer is Elusive

- Cancer is one of the leading causes of death
- Cancer is heterogeneous
- Finding biomarkers is like waiting for Godot
- Diagnosis is invasive and often too late
- There is no accurate, non-invasive diagnostic tool
- No effective early detection tool exists
- No holistic diagnosis method is available

Universal Diagnosis and Early Detection

- Early detection saves lives and resources
- Our method applies to all cancer types
- We use a scientific, evolutionary method that accounts for the heterogeneity of cancer
- We apply phylogentic principles, a well established and proven method in many scientific fields, to cancer data analysis

Worldwide Holistic Cancer Screening

- Initial investment to setup a master cladogram, to form a baseline for diagnosis, for each type of cancer is minimal
- Offer diagnosis and early detection for ten most common types of cancer with one single lab visit
- \$350 per screening of ten most common cancers



Our Method and Our Journey

- 2005 initial discovery; 2007 patent application; 2014 patent granted
- 2014-2024 creation of universal diagnosis and early detection tool
- We can build on the patent and extend it
- Published papers in peer-reviewed journals
- Conducted a clinical study for prostate cancer with 98% accuracy
- Successfully applied our method to hundred of publically available datasets

Our Profit From Each Screening

- \$250 per screening for one cancer type
- \$450 per screening for ten most common cancer types
- 100K screening per year, that is \$45M in revenue per year
- At-risk population will need two to three screenings per year

Future Growth

- Our cloud-native, software solution is available worldwide
- FDA approval will open many doors
- Insurance companies will make this screening mandatory to save lives and costs
- Initial investment is caped while potential growth is umlimited

The Founders





Dr. Mones Abu-Asab Former Scientist at NIH

Mohamed Chaouchi IT Division Director at GSA

Dr. Hakima Amri Professor at Georgetown University School of Medicine

What We Need

- We are seeking \$5M
- Each master cladogram = \$200K x 10 (types of cancers) = \$2M
- Cloud-native solution = \$500k per year
- Company expenses = \$2.5M per year